A biomimetic approach for enhancing the in vivo half-life of peptidesNature Chemical Biology
AbstractThe tremendous therapeutic potential of peptides has not yet been realized, mainly owing to their short in vivo half-life. Although conjugation to macromolecules has been a mainstay approach for enhancing protein half-life, the steric hindrance of macromolecules often harms the binding of peptides to target receptors, compromising the in vivo efficacy. Here we report a new strategy for enhancing the in vivo half-life of peptides without compromising their potency. Our approach involves endowing peptides with a small molecule that binds reversibly to the serum protein transthyretin. Although there are a few molecules that bind albumin reversibly, we are unaware of designed small molecules that reversibly bind other serum proteins and are used for half-life extension in vivo. We show here that our strategy was effective in enhancing the half-life of an agonist for GnRH receptor while maintaining its binding affinity, which was translated into superior in vivo efficacy.
Citation InformationSravan C. Penchala, Mark R. Miller, Arindom Pal, Jin Dong, et al.. "A biomimetic approach for enhancing the in vivo half-life of peptides" Nature Chemical Biology Vol. 11 Iss. 10 (2015) p. 793 - 798 ISSN: 1552-4450
Available at: http://works.bepress.com/andreas-franz/57/